Biogen Inc. (BIIB)

216.69
10.00 4.50
NASDAQ : Health Technology
Prev Close 226.88
Open 225.10
Day Low/High 216.49 / 226.80
52 Wk Low/High 249.17 / 388.67
Volume 8.45M
Avg Volume 1.27M
Exchange NASDAQ
Shares Outstanding 196.71M
Market Cap 63.69B
EPS 21.60
P/E Ratio 14.86
Div & Yield N.A. (N.A)

Latest News

Biogen May Shed $18 Billion in Value After Scrapping Alzheimer's Drug Trial

Biogen May Shed $18 Billion in Value After Scrapping Alzheimer's Drug Trial

Biogen shares plunge Thursday, wiping nearly $20 billion in value from the biotech group, after it dropped a late-stage trial for a key Alzheimer's disease drug.

Powell and Company Can Influence the Macro, but Not the Micro

Powell and Company Can Influence the Macro, but Not the Micro

All the money in the world cannot change the fact that rising stock prices and falling earnings make the market more expensive.

Jim Cramer's Thoughts on Micron, Biogen, Apple and Tesla

Jim Cramer's Thoughts on Micron, Biogen, Apple and Tesla

Jim Cramer weighs in on Micron's earnings, Biogen's fall, Apple's upcoming event and Elon Musk.

Volatile Biogen Stock Plunges $90: Here's the Trade I'm Considering

Volatile Biogen Stock Plunges $90: Here's the Trade I'm Considering

Biogen shareholders are taking a beating on cancellation of trials for its Alzheimer's drug candidate.

Jim Cramer Breaks Down Micron, Biogen and Apple

Jim Cramer Breaks Down Micron, Biogen and Apple

Jim Cramer has his eyes on Micron's earnings, Biogen's disappointment and Apple's upcoming event.

What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?

What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?

Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.

Biogen Could Go Either Way - Mixed Indicators and Charts

Biogen Could Go Either Way - Mixed Indicators and Charts

Let's check to see what can be gleaned.

Dow Tumbles as Rally Spurred by Trade Deal Hopes Fades

Dow Tumbles as Rally Spurred by Trade Deal Hopes Fades

Stocks recoup some losses in late trading but close lower as momentum from a report that China and the U.S. are in the final stages of completing a trade deal fades.

Nightstar Soars as Biogen to Buy Gene Therapy Company for $877 Million

Nightstar Soars as Biogen to Buy Gene Therapy Company for $877 Million

Biogen will purchase Nightstar Therapeutics in an all-cash deal that values the British gene-therapy company at $877 million.

Biogen Becomes #43 Most Shorted Nasdaq 100 Component, Replacing Regeneron Pharmaceuticals

Biogen Becomes #43 Most Shorted Nasdaq 100 Component, Replacing Regeneron Pharmaceuticals

The most recent short interest data has been released for the 01/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.

Biogen And Skyhawk Therapeutics Announce Agreement To Develop Novel Small Molecule RNA Splicing Modifiers For Neurological Disease Targets

Biogen And Skyhawk Therapeutics Announce Agreement To Develop Novel Small Molecule RNA Splicing Modifiers For Neurological Disease Targets

- Biogen made a one-time upfront $74 million payment to Skyhawk for research services and an exclusive license to therapeutic candidates for multiple sclerosis, spinal muscular atrophy and other neurological diseases to be developed using Skyhawk's...

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Biogen's Slump Is Likely to Continue

Biogen's Slump Is Likely to Continue

Avoid the long side of Biogen as the October low is likely to be tested or broken in the days ahead.

The Real Money Post-Industrial Average Has Jumped 11% So Far This Year

The Real Money Post-Industrial Average Has Jumped 11% So Far This Year

For the month of November RMPIA climbed 1.2% month over month.

Real Money Post-Industrial Average Beat Nasdaq Comp in November's First Half

Real Money Post-Industrial Average Beat Nasdaq Comp in November's First Half

Our index of 30 cutting-edge companies fell ... but not as much as the Nasdaq did.

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.

Colgate-Palmolive, Biogen Idec, Covanta: 'Mad Money' Lightning Round

Colgate-Palmolive, Biogen Idec, Covanta: 'Mad Money' Lightning Round

Jim Cramer weighs in on Colgate-Palmolive, Biogen Idec, Covanta, Cypress Semiconductor, Carrizo Oil & Gas, Allstate and more.

Biogen Becomes #41 Most Shorted Nasdaq 100 Component, Replacing Booking Holdings

Biogen Becomes #41 Most Shorted Nasdaq 100 Component, Replacing Booking Holdings

The most recent short interest data has been released for the 10/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Spirit Airlines, Southwest, Amgen: 'Mad Money' Lightning Round

Spirit Airlines, Southwest, Amgen: 'Mad Money' Lightning Round

Jim Cramer weighs in on Spirit Airlines, Southwest, Amgen, Biogen Idec, Liberty Oilfield Services, The Chefs Warehouse, Under Armour and more.

Reasons for This Rally: Cramer's 'Mad Money' Recap (Tuesday 9/18/18)

Reasons for This Rally: Cramer's 'Mad Money' Recap (Tuesday 9/18/18)

Jim Cramer says news on tariffs, FANG stocks, positive research, and the corporate outlook are fueling a stock market surprise.

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Dow Ends Off 125 Points as Caterpillar, 3M Earnings Disappoint

Dow Ends Off 125 Points as Caterpillar, 3M Earnings Disappoint

The Dow Jones Industrial Average falls Tuesday after earnings disappoint. The S&P 500 falls for the 12th time in 14 sessions.

Stocks Sink, Caterpillar, McDonald's, Arconic and Bayer - 5 Things You Must Know

Stocks Sink, Caterpillar, McDonald's, Arconic and Bayer - 5 Things You Must Know

U.S. stock futures tumble sharply as investors focus on slowing economic growth and simmering geopolitical tensions; Caterpillar, McDonald's, Verizon and 3M report earnings; Arconic is mulling an $11 billion offer from Apollo, a report says; a judge cuts the jury award against Bayer's Roundup.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

TheStreet Quant Rating: B (Buy)